Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2000

View Archived Issues

Eos and collaborators identify novel genes involved in immune system regulation

Evidence obtained by Gliatech supporting the role of inflammation in AD

Biovector Therapeutics and BioChem Pharma to develop S. pneumoniae nasal vaccine

High- vs. low-dose enalapril compared for immunological effects in CHF

Aventis Pasteur changes focus to second-generation Lyme disease vaccine

SB and Asahi enter agreement for diabetes/obesity compounds

Preliminary results of phase III Nyotran clinical trial

Aventis and MediGene to codevelop melanoma vaccine

Inflazyme updates R&D programs at BIO conference

Pharmacia & Upjohn launches two new breast cancer treatments during Q4 1999

Blockade of VEGF alone is sufficient to prevent blinding illness

Neurogen updates drug development programs in partnership with Pfizer

HemispheRx Biopharma files HIV Emergency Treatment IND with FDA

Boston Life Sciences describes positive preclinical findings with new antiparkinsonian

NCBE inhibitors in development at Aventis

The Liposome Company meets with FDA to discuss Evacet NDA

Phosphinic/phosphonic acids as MMP inhibitors

Hong Kong researchers present new antimalarial artemisinin derivatives

Selective 5-HT1D receptor ligands discovered by Allelix (NPS Allelix)

MS&D patents new class of selective human 5-HT2A receptor antagonists

Novel class of antiinflammatory therapeutics emerges from R&D at Centaur

L-Nucleoside ribavirin analogues are able to enhance type 1 cytokine production

Caspase inhibitors protect against neuronal injury after focal cerebral ischemic insult